TNFSF11 and Arthritis: Anti-RANKL therapy, however, consistently fails to influence inflammatory parameters within arthritic joints of experimental arthritis models, despite its ability to prevent arthritis-related bone loss in the face of ongoing inflammation [21,22,24,26,45,52,53].